Institutional members access full text with Ovid®

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes

Poveda, Evaa; de Mendoza, Carmena; Parkin, Neilb; Choe, Sunnyb; García-Gasco, Pilara; Corral, Angélicaa; Soriano, Vincenta

doi: 10.1097/QAD.0b013e3282f51eb9
Clinical Science

Background: Tipranavir (TPV) and darunavir (DRV) are potent against protease inhibitor (PI)-resistant viruses. Efficacy of these compounds when confronting distinct HIV subtypes is not known.

Methods: All clinical specimens from HIV-positive patients sent to our institution for drug resistance testing between 1999 and 2006 were analysed. The prevalence of TPV and DRV resistance mutations was assessed based on the latest International AIDS Society-USA panel list. Phenotypic susceptibility to DRV and TPV was examined in a subset of these samples using the PhenoSense assay.

Results: A total of 1364 genotypes were analysed, including 1178 from individuals infected with clade B (285 drug naive) and 186 with non-B subtypes (137 drug naive). The mean number (±SD) of DRV resistance-associated mutations was higher in clade B than non-B (0.4 ± 0.9 versus 0.06 ± 0.3; P < 0.001), and more frequent among PI-experienced than drug-naive patients (0.6 ± 1.02 versus 0.02 ± 0.21; P < 0.001). In contrast, the mean number of TPV resistance-associated mutations was higher in non-B than B subtypes (2.7 ± 1 versus 1.2 ± 1.6; P < 0.001), regardless of PI experience. Susceptibility to TPV and DRV was examined in 29 drug-naive patients infected with non-B subtypes (1A, 3C, 2CRF01_AE, 9CRF02_AG, 1CRF12_BF, 3CRF14_BG, 3F and 7G). All showed susceptibility to DRV and 93% to TPV. Interestingly, two subtype F specimens showed reduced TPV susceptibility, with fold-changes of 2.7 and 2.1, respectively.

Conclusions: Non-B subtypes show a greater number of TPV resistance-associated mutations than B viruses, regardless of PI exposure. While HIV clade has no influence on DRV susceptibility, some F subtypes may show reduced TPV susceptibility.

From the aDepartment of Infectious Diseases, Hospital Carlos III, Madrid, Spain

bMonogram Biosciences, South San Francisco, California, USA.

Received 15 October, 2007

Revised 30 November, 2007

Accepted 4 December, 2007

Correspondence to Dr E. Poveda, Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado, 10, Madrid 28029, Spain. E-mail:

© 2008 Lippincott Williams & Wilkins, Inc.